Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.7
4.3
Journals
Pharmaceuticals
Special Issues
Nanotechnology in Biomedical Applications
share announcement

Nanotechnology in Biomedical Applications

A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Pharmaceutical Technology".

Deadline for manuscript submissions: 25 November 2025 | Viewed by 1821

Special Issue Editor

Dr. Luciano Paulino Silva

E-Mail Website
Guest Editor
Laboratory of Nanobiotechnology, Embrapa Genetic Resources and Biotechnology, Brasília 70770-917, DF, Brazil
Interests: nanovesicles; antioxidant activity; nanoparticles; biomaterials
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

This Special Issue, entitled "Nanotechnology in Biomedical Applications", aims to showcase the transformative impact of nanotechnology on health sciences, with a focus on advancements in diagnostics, therapeutics, and theranostics, and evaluations of nanomaterials' impacts on health at the cellular and organism levels. Recent developments in nanostructured materials, nanobiosensors, and nanocarriers offer new pathways to address critical biomedical challenges, including targeted drug delivery, early disease detection, and nanosafety. Through an interdisciplinary approach, this Special Issue will explore innovative nano-enabled solutions designed to improve treatment specificity and efficacy, minimize side effects, and advance healthcare. It will bring together contributions on novel nanomaterials, in vitro and in vivo studies, and translational research that bridges the gap between experimental findings and clinical applications, aligning with our commitment to sustainable and accessible health technologies.

Dr. Luciano Paulino Silva
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • nanotechnology
  • nanobiotechnology
  • biomedical applications
  • drug delivery
  • nanobiosensors
  • targeted therapy
  • diagnostics
  • nanomaterials
  • therapeutics
  • theranostics

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

20 pages, 9461 KiB  
Article
Enhanced Topical Delivery of Methotrexate via Transferosome-Loaded Microneedle Array Patch: Formulation, Optimization, and In Vitro–In Vivo Assessment
by Snehal Shinde, Anil Kumar Singh, Vijay R. Chidrawar, Amarjitsing Rajput and Sudarshan Singh
Pharmaceuticals 2025, 18(4), 594; https://doi.org/10.3390/ph18040594 - 18 Apr 2025
Cited by 1 | Viewed by 683
Abstract
Background: Conventional approaches in treating psoriasis demonstrate several complications. methotrexate (MTX) has been frequently used for its efficacy in managing moderate to severe psoriasis. However, MTX acts as an antagonist in regular dosage, which creates a patient compliance issue with undesirable consequences for [...] Read more.
Background: Conventional approaches in treating psoriasis demonstrate several complications. methotrexate (MTX) has been frequently used for its efficacy in managing moderate to severe psoriasis. However, MTX acts as an antagonist in regular dosage, which creates a patient compliance issue with undesirable consequences for patients, which necessitates development of an innovative approach to enhance skin permeation. Therefore, this study examines the improved topical administration of MTX utilizing a transferosome-loaded microneedle (MNs) array patch for the management of psoriasis. Methods: A design of experiment was used assess the effect of phospholipid content and edge activator type on vesicle size and entrapment efficiency (EE) to fabricate and optimize transferosome-loaded MTX. Furthermore, the MTX was incorporated within MNs and assessed for in vitro-ex vivo-in vivo parameters. Results: The morphology result revealed vesicles mean diameter of 169.4 ± 0.40 nm and EE of 69 ± 0.48 (%). Compared to traditional formulations (MTX patch and gel), the optimized transferosome-loaded dissolving MN array patch showed a substantial increase in diffusion of MTX tested over rat skin. Furthermore, an enhanced therapeutic benefit at the application site through cumulative drug release profiles suggested sustained release of MTX over 24 h. Moreover, in vivo experiments showed that the MN array patch exhibited higher accumulation, compared to conventional formulation tested. In addition, the plasma concentration measurements demonstrated a reduction in systemic exposure to MTX, diminishing the possibility of intricacy while preserving localized therapeutic efficacy. The capability of the MN array patch to lance the epidermal layers was proven by histological assessments. Conclusions: Thus, transferosome-loaded MNs is a viable method of delivering MTX topically with prolonged drug release and reduced systemic toxicity. Full article
(This article belongs to the Special Issue Nanotechnology in Biomedical Applications)
►▼ Show Figures

Graphical abstract

12 pages, 3205 KiB  
Article
Red Blood Cell-Based Delivery Systems for the Release of Hemoglobin-Derived Peptides with In Vitro Antitumor Activities
by Cínthia Caetano Bonatto, Graziella Anselmo Joanitti and Luciano Paulino Silva
Pharmaceuticals 2025, 18(4), 570; https://doi.org/10.3390/ph18040570 - 14 Apr 2025
Viewed by 450
Abstract
Background/Objectives: This study aimed to develop liposomes derived from lipids obtained from red blood cell membranes for potential use in antitumor applications. Hemoglobin hydrolysates exhibiting peptides with known antitumor activities were encapsulated within these liposomes. Methods: The developed liposomal systems were characterized by [...] Read more.
Background/Objectives: This study aimed to develop liposomes derived from lipids obtained from red blood cell membranes for potential use in antitumor applications. Hemoglobin hydrolysates exhibiting peptides with known antitumor activities were encapsulated within these liposomes. Methods: The developed liposomal systems were characterized by their physicochemical properties, including size, surface charge, and encapsulation efficiency, and tested in vitro against 4T1 breast cancer cells and NIH3T3 fibroblasts. Results: Results indicated that the liposomes achieved effective encapsulation (88.9%), with nanometer-scale sizes (ranging from 140.7 nm for Blank-Liposomes to 658.3 nm for Pep-Liposomes) and stable colloidal properties. Conclusions: Although cytotoxicity was limited, the use of liposomes from endogenous components, such as red blood cells, demonstrates promise as a complementary approach in anticancer therapy. Full article
(This article belongs to the Special Issue Nanotechnology in Biomedical Applications)
►▼ Show Figures

Figure 1

Review

Jump to: Research

16 pages, 2031 KiB  
Review
Nanodrug Delivery Systems for Acute Lymphoblastic Leukemia Therapy
by Aiyun Yang, Yuanfang Lu, Zuo Zhang and Jianhua Wang
Pharmaceuticals 2025, 18(5), 639; https://doi.org/10.3390/ph18050639 - 27 Apr 2025
Viewed by 375
Abstract
Acute lymphoblastic leukemia (ALL) is a malignant tumor caused by abnormal proliferation of B-line or T-line lymphocytes in the bone marrow. Traditional treatments have limitations. Because of their unique advantages, nanodrug delivery systems (NDDSs) show great potential in the treatment of ALL. In [...] Read more.
Acute lymphoblastic leukemia (ALL) is a malignant tumor caused by abnormal proliferation of B-line or T-line lymphocytes in the bone marrow. Traditional treatments have limitations. Because of their unique advantages, nanodrug delivery systems (NDDSs) show great potential in the treatment of ALL. In this paper, the pathological features of ALL, the limitations of current therapeutic methods, and the definition and composition of NDDSs were reviewed. Research strategies for the use of NDDSs in the treatment of ALL were discussed. In addition, challenges and future development directions of NDDSs in the treatment of ALL were also discussed, aiming to provide reference for the application of NDDSs in the diagnosis and treatment of ALL. Full article
(This article belongs to the Special Issue Nanotechnology in Biomedical Applications)
►▼ Show Figures

Graphical abstract

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop